ChiCTR2300068316: A multicenter, randomized, placebo-controlled clinical study to evaluate the safety and efficacy of HL231 inhalation solution in the treatment of chronic obstructive pulmonary disease (COPD) |
|
|
| Not yet recruiting | 2 | 18 | | B, F, D (B: 261 μg/141 μg HL231 inhalation solution; D: Jierun Ultibro 110 μg/50 μg); F: 261 μg/120 μg HL231 inhalation solution) ;D, B, F (B: 261 μg/141 μg HL231 inhalation solution; D: Jierun Ultibro 110 μg/50 μg); F: 261 μg/120 μg HL231 inhalation solution) ;F, D, B (B: 261 μg/141 μg HL231 inhalation solution; D: Jierun Ultibro 110 μg/50 μg); F: 261 μg/120 μg HL231 inhalation solution) ;D, F, B (B: 261 μg/141 μg HL231 inhalation solution; D: Jierun Ultibro 110 μg/50 μg); F: 261 μg/120 μg HL231 inhalation solution) ;F, B, D (B: 261 μg/141 μg HL231 inhalation solution; D: Jierun Ultibro 110 μg/50 μg); F: 261 μg/120 μg HL231 inhalation solution) ;B, D, F (B: 261 μg/141 μg HL231 inhalation solution; D: Jierun Ultibro 110 μg/50 μg); F: 261 μg/120 μg HL231 inhalation solution) | West China Hospital, Sichuan University; West China Hospital, Sichuan University, Haisco Pharmaceutical Group Co., Ltd. | Chronic obstructive pulmonary disease (COPD) | | | | |
